Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Blood (2024) 144 (Supplement 1): 567.

https://doi.org/10.1182/blood-2024-207439

Published: 2024

Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

John Radford, Joanna Williams, Darren Edwards, Ruth Pettengell, Peter Johnson, Peter Hoskin, Timothy Illidge, Nicholas Counsell

Blood (2024) 144 (Supplement 1): 457.

https://doi.org/10.1182/blood-2024-200662

Published: 2024

Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford

Blood (2023) 142 (Supplement 1): 3058.

https://doi.org/10.1182/blood-2023-173320

Published: 2023

Journal Articles

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Dima El-Sharkawi, Tasneem Elnafie, Sarah Thompson, Louise Stanton, Nicholas Counsell, Amit Sud, Ian Chau, Bhupinder Sharma, Peter Johnson, David C. Linch, Sunil Iyengar, Andrew Davies, David Cunningham

Blood (2022) 140 (Supplement 1): 7908–7909.

https://doi.org/10.1182/blood-2022-167852

Published: 2022

Journal Articles

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Kim M Linton, MBChB, PhD, Joanna M Oladipo, PhD, Nicholas Counsell, MSc, Janet Taylor, PhD, Cathy Burton, MBBChir, MA, MD FRCPath, Rachel Oakley, PhD, Joanna Williams, PhD, Sally F Barrington, Prof, MD PhD, Richard Byers, BSc, MSc, MBChB, PhD FRCPath, Timothy Illidge, MDPhD, John A. Radford, MD FMedSci

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136318

Published: 2020

Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch

Blood (2018) 132 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2018-99-111824

Published: 2018

Journal Articles

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Blood (2018) 132 (20): 2154–2165.

https://doi.org/10.1182/blood-2018-05-849893

Published: 2018

Includes: Supplemental data

Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Blood (2017) 130 (Supplement 1): 1864.

https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864

Published: 2017

Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Blood (2017) 130 (Supplement 1): 267.

https://doi.org/10.1182/blood.V130.Suppl_1.267.267

Published: 2017

Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong

Blood (2016) 128 (22): 4508.

https://doi.org/10.1182/blood.V128.22.4508.4508

Published: 2016

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

Andrea Kühnl, MD, Ridwan Shaikh, David Cunningham, Sharon L Barrans, Cathy H Burton, Andrew Jack, Mary Gleeson, Nicholas Counsell, Paul Smith, Oliver Schofield, David C. Linch, FRCP, Michael Hubank, PhD

Blood (2016) 128 (22): 1747.

https://doi.org/10.1182/blood.V128.22.1747.1747

Published: 2016

Journal Articles

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

Dunnya De-Silva, MBBS, Adam Bloomfield, Nicholas Counsell, Simon Cheesman, BPharm, Ali Rismani, MBBS, Neil Rabin, Shirley D'Sa, Charalampia Kyriakou, Jayne Galinsky, Sarah Richard, Rakesh Popat, Atul Mehta, MD, Kwee L Yong

Blood (2016) 128 (22): 5684.

https://doi.org/10.1182/blood.V128.22.5684.5684

Published: 2016

Journal Articles

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study

Rebecca L Auer, MD PhD, Roger G Owen, Shirley D'Sa, Guy Pratt, MD FRCP FRCPath, Bilyana Popova, Laura Clifton Hadley, Oliver Schofield, Nicholas Counsell, Paul Smith

Blood (2016) 128 (22): 618.

https://doi.org/10.1182/blood.V128.22.618.618

Published: 2016

Journal Articles

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Selina J Chavda, MBBS BSc MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Pavlina Mesiri, MSc, Nicholas Counsell, Jaimal Kothari, FRCPath, Antonia Bird, Ciaran Mariner, Anastasia Chew, MBBS, MRCP, FRCPATH, Katherine Clesham, MBBS, Sally Moore, BSc, FRPATH, FRCP, MBBS, Laura Percy, MBBS, MRCP, FRCPATH, Ali Rismani, MBBS, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong

Blood (2016) 128 (22): 3465.

https://doi.org/10.1182/blood.V128.22.3465.3465

Published: 2016

Journal Articles

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Blood (2016) 128 (22): 3267.

https://doi.org/10.1182/blood.V128.22.3267.3267

Published: 2016

Journal Articles

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Blood (2015) 126 (23): 1516.

https://doi.org/10.1182/blood.V126.23.1516.1516

Published: 2015

Journal Articles

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Blood (2014) 124 (21): 4745.

https://doi.org/10.1182/blood.V124.21.4745.4745

Published: 2014

Journal Articles

Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk

Paul M Maciocia, MRCP, Nicholas Counsell, Antonia Bird, Laura Percy, Sally Moore, BSc, FRPATH, FRCP, MBBS, Neil Rabin, Shirley D'Sa, MD, Manuel Rodriguez-Justo, Kwee L Yong, PhD

Blood (2013) 122 (21): 2159.

https://doi.org/10.1182/blood.V122.21.2159.2159

Published: 2013

Journal Articles

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671

William M Townsend, MRCP, Roderick J. Johnson, MD, Nicholas Counsell, Humra Shah, Bryson Pottinger, Katy Evans, Caroline Wickham, Paul Smith, Rudin Claudius, MD FRCP FRCPath

Blood (2012) 120 (21): 3642.

https://doi.org/10.1182/blood.V120.21.3642.3642

Published: 2012

NARROW

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of WaldenstrőM's Macroglobulinemia: A Randomised Phase II Study

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Single Centre Analysis Of Autologous Stem Cell Transplant Outcomes In Multiple Myeloma In 338 Consecutive Patients: Maintenance/Consolidation Is Associated With Superior Survival, But Early Relapse Is The Single Most Important Predictor Of Survival and May Override Genetic Risk

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only